Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma

Jaudah Al-Maghrabi; Zuhoor Al-Mansouri; Abdullah Al-Harbi; Mourad Assidi; Abdelbaset Buhmeida; Wafaey Gomaa

doi:10.5114/pjp.2022.117172

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2022
vol. 73

Send email

Copy url:

abstract:

Original paper

Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma

Jaudah Al-Maghrabi

^{1, 2}

,

Zuhoor Al-Mansouri

²

,

Abdullah Al-Harbi

³

,

Mourad Assidi

^{4, 5}

,

Abdelbaset Buhmeida

^{4, 5}

,

Wafaey Gomaa

⁶

Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia

Department of Pathology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

Department of Pathology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia

Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

Department of Pathology, Faculty of Medicine, Minia University, Al Minia, Egypt

Pol J Pathol 2022; 74 (1): 14-20

DOI: https://doi.org/10.5114/pjp.2022.117172

Online publish date: 2022/06/28

View full text Get citation

PlumX metrics:

Glypicans (GPC) are involved in the developmental morphogenesis and regulatory processes of cell signalling. Abnormal expression has been observed in different cancer types.

One hundred and thirty-seven colorectal carcinoma (CRC) and 44 nodal metastases were used to create tissue microarrays. Immunohistochemistry was done to detect and evaluate the impact of immunostaining patterns of GPC-3 protein in CRC.

GPC-3 immunostaining is increased in CRC and nodal metastasis (p < 0.001) and was not association with clinicopathological parameters. GPC-3 immunostaining was associated with longer disease-free survival (p = 0.021) and overall survival (p = 0.05).

For the first time, we show GPC-3 immunostaining association with survival outcomes in CRC. GPC-3 may be used as an independent prognostic factor for survival in CRC.

keywords:

Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma

Jaudah Al-Maghrabi 1, 2 , Zuhoor Al-Mansouri 2 , Abdullah Al-Harbi 3 , Mourad Assidi 4, 5 , Abdelbaset Buhmeida 4, 5 , Wafaey Gomaa 6

glypican-3, colorectal carcinoma, immunostaining, survival

Jaudah Al-Maghrabi

^{1, 2}

,

Zuhoor Al-Mansouri

²

,

Abdullah Al-Harbi

³

,

Mourad Assidi

^{4, 5}

,

Abdelbaset Buhmeida

^{4, 5}

,

Wafaey Gomaa

⁶